Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Change in Intangibles (2016 - 2025)

Historic Change in Intangibles for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to -$251.0 million.

  • Astrazeneca's Change in Intangibles fell 161.94% to -$251.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.1 billion, marking a year-over-year decrease of 1626.6%. This contributed to the annual value of -$3.1 billion for FY2025, which is 1626.6% down from last year.
  • Per Astrazeneca's latest filing, its Change in Intangibles stood at -$251.0 million for Q4 2025, which was down 161.94% from -$1.0 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Change in Intangibles peaked at -$65.0 million during Q2 2021, and registered a low of -$1.3 billion during Q2 2025.
  • Over the past 5 years, Astrazeneca's median Change in Intangibles value was -$342.5 million (recorded in 2021), while the average stood at -$546.0 million.
  • Per our database at Business Quant, Astrazeneca's Change in Intangibles plummeted by 74930.56% in 2023 and then surged by 5454.55% in 2025.
  • Over the past 5 years, Astrazeneca's Change in Intangibles (Quarter) stood at -$395.0 million in 2021, then increased by 26.58% to -$290.0 million in 2022, then rose by 26.55% to -$213.0 million in 2023, then dropped by 15.96% to -$247.0 million in 2024, then fell by 1.62% to -$251.0 million in 2025.
  • Its Change in Intangibles stands at -$251.0 million for Q4 2025, versus -$1.0 billion for Q3 2025 and -$1.3 billion for Q2 2025.